187 related articles for article (PubMed ID: 33618387)
1. Surgical Aspects in Gene Therapy for Inherited Retinal Diseases.
Fischer MD; Bartz-Schmidt KU; Dimopoulos S; Herrmann P; Gerhardt M; Holz FG; Priglinger S
Klin Monbl Augenheilkd; 2021 Mar; 238(3):267-271. PubMed ID: 33618387
[TBL] [Abstract][Full Text] [Related]
2. An Economic Evaluation of Voretigene Neparvovec for the Treatment of Biallelic RPE65-Mediated Inherited Retinal Dystrophies in the UK.
Viriato D; Bennett N; Sidhu R; Hancock E; Lomax H; Trueman D; MacLaren RE
Adv Ther; 2020 Mar; 37(3):1233-1247. PubMed ID: 32034665
[TBL] [Abstract][Full Text] [Related]
3. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
4. [Implementation of a new gene therapy in ophthalmology: Regulatory and organizational issues].
Daruich A; Boinet R; Falcou C; Cotteret C; Magassa A; Schlatter J; Escalup R; Cisternino S; Valleix S; Robert MP; Bremond-Gignac D
J Fr Ophtalmol; 2021 May; 44(5):730-737. PubMed ID: 33838946
[TBL] [Abstract][Full Text] [Related]
5. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy in ophthalmology].
Priglinger CS; Gerhardt MJ; Rudolph G; Priglinger SG; Michalakis S
Ophthalmologie; 2023 Aug; 120(8):867-882. PubMed ID: 37418021
[TBL] [Abstract][Full Text] [Related]
7. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
8. Frequency of
Kahraman NS; Öner A; Özkul Y; Dündar M
Turk J Ophthalmol; 2022 Aug; 52(4):270-275. PubMed ID: 36017377
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy for hereditary eye diseases].
Kessel L; Bertelsen M; Klemp K; Christensen UC
Ugeskr Laeger; 2022 Nov; 184(45):. PubMed ID: 36345897
[TBL] [Abstract][Full Text] [Related]
10. Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal.
Farmer C; Bullement A; Packman D; Long L; Robinson S; Nikram E; Hatswell AJ; Melendez-Torres GJ; Crathorne L
Pharmacoeconomics; 2020 Dec; 38(12):1309-1318. PubMed ID: 32875526
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
12. RNA-Based Therapeutic Strategies for Inherited Retinal Dystrophies.
Garanto A
Adv Exp Med Biol; 2019; 1185():71-77. PubMed ID: 31884591
[TBL] [Abstract][Full Text] [Related]
13. Gene Therapy in Retinal Dystrophies.
Ziccardi L; Cordeddu V; Gaddini L; Matteucci A; Parravano M; Malchiodi-Albedi F; Varano M
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739639
[TBL] [Abstract][Full Text] [Related]
14. Retinal gene therapy in RPE-65 gene mediated inherited retinal dystrophy.
Jalil A; Ivanova T; Moussa G; Parry NRA; Black GCM
Eye (Lond); 2023 Jun; 37(9):1874-1877. PubMed ID: 36163489
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and Adverse Effects of Voretigene Neparvovec Treatment for Biallelic
Kiraly P; Cottriall CL; Taylor LJ; Jolly JK; Cehajic-Kapetanovic J; Yusuf IH; Martinez-Fernandez de la Camara C; Shanks M; Downes SM; MacLaren RE; Fischer MD
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892166
[TBL] [Abstract][Full Text] [Related]
16. Voretigene neparvovec-rzyl for treatment of
Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
[No Abstract] [Full Text] [Related]
17. Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies.
Lee K; Garg S
Genet Med; 2015 Apr; 17(4):245-52. PubMed ID: 25790163
[TBL] [Abstract][Full Text] [Related]
18. The new landscape of retinal gene therapy.
Ku CA; Pennesi ME
Am J Med Genet C Semin Med Genet; 2020 Sep; 184(3):846-859. PubMed ID: 32888388
[TBL] [Abstract][Full Text] [Related]
19. Antisense Oligonucleotide Therapy for Inherited Retinal Dystrophies.
Gerard X; Garanto A; Rozet JM; Collin RW
Adv Exp Med Biol; 2016; 854():517-24. PubMed ID: 26427454
[TBL] [Abstract][Full Text] [Related]
20. [Specific gene therapy for hereditary retinal dystrophies - an update].
Stieger K; Lorenz B
Klin Monbl Augenheilkd; 2014 Mar; 231(3):210-5. PubMed ID: 24327302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
